COVID-19 survivors and kidney disease: The long term effects on kidney function, and health outcomes for people with pre-existing chronic kidney disease - a study using electronic health records
- Funded by Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR)
- Total publications:27 publications
Grant number: NIHR301535
Grant search
Key facts
Disease
COVID-19Start & end year
20212024Known Financial Commitments (USD)
$689,641.2Funder
Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR)Principal Investigator
N/A
Research Location
United KingdomLead Research Institution
London School of Hygiene and Tropical MedicineResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Post acute and long term health consequences
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Aims of my research I aim to investigate whether people who survive COVID-19 are more likely to lose kidney function, partially or completely; I also aim to build and test a prediction tool to work out which survivors are most likely to be at longer-term risk of serious declines in kidney function. I will also be investigating the impact of COVID-19 on survivors who had kidney disease before they became unwell, and whether this increases risk of experiencing bad outcomes earlier, such as death, complete kidney failure, heart attacks, and frailty. Background When people are admitted to hospital with COVID-19, one of the common consequences is kidney injury. We are not certain why, or whether this has long-term effects in survivors, but there are strong reasons to be concerned that it may. Long-term kidney damage, known as chronic kidney disease (CKD), is associated with earlier death and heart attacks. When CKD leads to kidney failure, people require dialysis or a kidney transplant to stay alive. This has a big impact on quality and length of life, and comes at great cost to the NHS. Therefore, we need to find out what the long-term risks of COVID-19 are to kidney function, and determine who is at the greatest risk so they can be closely monitored and treated. Design and methods A way of addressing important health concerns relatively quickly is by analysing health records which cover millions of people. In the UK, we have electronically coded GP records, and for most people, we can combine these with records from hospitals. I will use these anonymised records for two study populations: Study A: I will compare risks of change in kidney function or complete kidney failure between COVID-19 survivors and people of the same age, sex, and under the same GP. Study B: Among people with pre-existing CKD, I will compare risks of death, hospital admissions, complete kidney failure, heart attacks, blood clots, low red blood cell levels, and frailty between COVID-19 survivors to people who are the same age, sex, and have the same level of pre-existing CKD. I will replicate my work with records from Sweden to understand if the findings are specific to COVID-19 or influenced by factors such as health-care system and the characteristics of the local population. I will account for many other factors like age, ethnicity, socio-economic status and pre-existing medical problems like diabetes, to establish whether our results are likely to be due to COVID-19 itself, or were due to differences in who developed severe infection. I will apply statistical modelling to records from Study A to create a straightforward tool using information like routine test results or medical history, to predict which patients are most at risk of kidney failure. I will then test this model on another large set of records from the UK and from Sweden to ensure that it is reliable. Patient and public involvement My ideas have been informed by meetings including patients, and several patients are keen to join my advisory panel. I will ensure this includes COVID-19 survivors with and without CKD, and a member of public who has not had COVID-19. We will meet at the start of my research to finalise plans, and then I will update them of my progress every six months. I will seek their advice on how to ensure my findings reach other patients and the public. Dissemination Because this is a big, important study, I will share findings with the media, charities, healthcare professionals, and policy makers to ensure that it has maximum benefit for patients.
Publicationslinked via Europe PMC
Last Updated:41 minutes ago
View all publications at Europe PMC